All In Biotech

Drug Trial Radar · NCT05603910

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for Mismatch Repair Proficient (pMMR) Recurrent/Unresectable Endometrial Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Apr 15, 2023

Primary completion

Apr 15, 2029

Study completion Apr 15, 2034

Sponsor

Lead sponsor
Aaron WolfsonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation therapy, to support cancer cells in multiplying and spreading to other body sites.

Conditions

  • Recurrent Endometrial Carcinoma
  • Unresectable Endometrial Carcinoma

Interventions

  • LenvatinibDrug

    Lenvatinib will be self-administered orally (PO) by participants in a 3+3 escalation/de-escalation design. Participants will receive one of the following four dose levels: * Dose level 1: 4 mg * Dose level 2: 8 mg * Dose level 3: 12 mg (Starting dose) * Dose level 4: 16 mg

  • PembrolizumabDrug

    Pembrolizumab 200 mg will be administered intravenously (IV) once on Days 1, 22 and 43.

  • Hypofractionated External Beam Radiation TherapyRadiation

    Whole pelvic HypoFx EBRT consisting of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 17.5 Gy, delivered to site(s) of gross disease of at least 1.0 cm in size.

  • High-Dose Rate (HDR) BrachytherapyRadiation

    Vaginal high-dose rate (HDR) brachytherapy administered per standard of care (SoC) techniques.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D) of LenvatinibTime frame: Up to 12 weeks
  2. Number of Participants Experiencing Treatment-Related Toxicity: Dose-Limiting Toxicities (DLTs)Time frame: Up to 12 weeks
  3. Number of Participants Experiencing Treatment-Related Toxicity: Adverse Events (AEs)Time frame: Up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.